Bradykinin may be involved in neuropeptide Y-induced diuresis, natriuresis, and calciuresis.
Neuropeptide Y (NPY) can cause diuresis, natriuresis, and calciuresis in rats independently of the pressure-natriuresis mechanism (A. Bischoff and M. C. Michel. Pflügers Arch. 435: 443-453, 1998). Because this is seen in systemic but not intrarenal NPY infusion, we have investigated the possible mediator of tubular NPY effects in anesthetized rats. In the present study, infusion of NPY (2 micrograms . kg-1 . min-1) enhanced renovascular resistance by approximately 8 mmHg . ml-1 . min and enhanced urine and sodium excretion by approximately 450 microliter/15 min and approximately 60-85 micromol/15 min, respectively. Acute renal denervation did not alter renovascular or tubular NPY effects, indicating that a neuronally released mediator is not involved. Treatment with the angiotensin II-receptor antagonist losartan prevented the decline of the renovascular response with time but did not modify tubular NPY effects. The bradykinin B2-receptor antagonist icatibant accelerated the decline of the renovascular NPY effects with time; concomitantly, it attenuated NPY-induced diuresis and natriuresis and abolished NPY-induced calciuresis. The converting-enzyme inhibitor ramiprilat prevented the decline of the renovascular response with time; concomitantly, it magnified the NPY-induced diuresis, natriuresis, and calciuresis. We conclude that bradykinin may be involved in NPY-induced diuresis, natriuresis, and, in particular, calciuresis.
Department of Medicine, University of Essen, 45122 Essen, Germany.
A
A
Bischoff
W
W
Rascher
M C
MC
Michel
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000818:Animals; D001920:Bradykinin / Q000031:analogs & derivatives / Q000494:pharmacology / Q000502:physiology*; D065168:Bradykinin Receptor Antagonists; D002118:Calcium / Q000652:urine; D003404:Creatinine / Q000378:metabolism; D003714:Denervation; D004231:Diuresis / Q000187:drug effects / Q000502:physiology*; D007262:Infusions, Intravenous; D007668:Kidney / Q000187:drug effects / Q000294:innervation / Q000502:physiology*; D019808:Losartan / Q000494:pharmacology; D008297:Male; D009318:Natriuresis / Q000187:drug effects / Q000502:physiology*; D009478:Neuropeptide Y / Q000008:administration & dosage / Q000494:pharmacology / Q000502:physiology*; D017257:Ramipril / Q000031:analogs & derivatives / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D043782:Receptor, Bradykinin B2; D012039:Regional Blood Flow; D012079:Renal Circulation / Q000187:drug effects / Q000502:physiology*; D014655:Vascular Resistance
D000806:Angiotensin-Converting Enzyme Inhibitors; D065168:Bradykinin Receptor Antagonists; D009478:Neuropeptide Y; D043782:Receptor, Bradykinin B2; C052549:ramiprilat; C065679:icatibant; D003404:Creatinine; D019808:Losartan; D017257:Ramipril; D001920:Bradykinin; D002118:Calcium